Figure 3 | Scientific Reports

Figure 3

From: Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection

Figure 3

Kinetics of antibody responses against SARS-CoV-2 in hospitalized COVID-19 patients. Hospitalized COVID-19 patients include non-ICU, ICU and deceased COVID-19 patients. (a,h) Percentage of seropositivity (a) and percentage of patients with neutralizing antibodies (h) in hospitalized COVID-19 patients, according to time between symptom onset and sample collection. Seropositivity corresponds to the presence of anti-RBD and/or anti-N antibodies in serum/plasma. Serum/plasma collection was performed 0–4 days post-symptoms onset (PSO) in 9 patients, 5–9 days PSO in 31 patients, 10–15 days PSO in 42 patients and more than 15 days PSO in 16 patients. (b–g,i) Titers of anti-RBD IgG (b), IgM (c) and IgA (d), titers of anti-N IgG (e), IgM (f) and IgA (g) and spike-pseudotyped lentiviral neutralization (i) in hospitalized COVID-19 patients according to the time between symptom onset and sample collection. Each dot represents one sample. Dashed line represents the positivity threshold. The preferred model for best fit curve (solid line) was assessed by an extra sum-of-squares F test and is a semi-log line (b–g) or a one-phase association (i). The Spearman’s correlation coefficient (r) is shown. ***p < 0.001, ****p < 0.0001 (Spearman test).

Back to article page